Palace: 600,000 doses of Sinovac's Covid-19 vaccine arriving on Feb. 23 | Inquirer News
Close  

Palace: 600,000 doses of Sinovac’s Covid-19 vaccine arriving on Feb. 23

By: - Reporter / @DYGalvezINQ
/ 01:06 PM February 11, 2021

MANILA, Philippines — A total of 600,000 doses of China-based Sinovac Biotech’s Covid-19 vaccine  are set to arrive in the country on Feb. 23, Malacañang announced on Thursday.

ADVERTISEMENT

Presidential spokesman Harry Roque said the Chinese government donated 100,000 doses to the Department of National Defense (DND).

“Ang bakuna na Sinovac na galing sa China, nakaukit na sa bato ang pagdating, ito ay sa 23 ng Pebrero,” Roque said in a Palace briefing.

FEATURED STORIES

(The Sinovac vaccine which will come from China will arrive on Feb. 23)

Harry Roque

Presidential spokesperson Harry Roque (FILE PHOTO)

To date, Sinovac has not yet secured an emergency use authorization (EUA) from the Food and Drug Administration. This is required before a vaccine can be legally administered in the country.

So far, only the Covid-19 vaccines of Pfizer-BioNTech and British drugmaker AstraZeneca have secured EUAs in the country.

Sinovac’s efficacy rate varied from 50.4%, 65%, and 91.25% in trials in Brazil, Indonesia, and Turkey.

“Sa 23 ng Pebrero darating ang Sinovac, 600,000, mayroong 100,000 ay donasyon ng Tsina para sa kasundaluhan sa DND,” he said.

(On Feb. 23, 600,000 doses of Sinovac vaccine will arrive, 100,000 of which is a donation from Chinese government to the DND.)

gsg/edv
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: coronavirus vaccine, emergency use authorization (EUA), Feb. 23, Palace, Roque, Sinovac
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.